Heparinization vs Salinization of the Peripheral Venous Catheter

Launched by CONSORCI SANITARI DE L'ALT PENEDÈS I GARRAF · Jan 13, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the best way to keep intravenous catheters (thin tubes inserted into veins) from getting blocked. Researchers want to see if using saline (a saltwater solution) is just as effective as using a low dose of heparin (a medication that helps prevent blood clots) to keep these catheters working properly. The trial will involve about 3,450 patients at a hospital in Catalonia, Spain, and will compare how many catheters need to be removed because they are blocked in both groups.

To participate in this trial, patients must be at least 18 years old and have a peripheral venous catheter for treatment. However, some people won't be eligible, such as those who are allergic to heparin, undergoing dialysis, or have certain serious health conditions. Participants will be randomly assigned to either the saline or heparin group and will help researchers learn more about which method is better at preventing problems with catheters. It's important for potential participants to give their written consent before joining the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients older than 18 yo, admitted to the Hospital Residencia Sant Camil
• • Patients with at least one peripheral venous line for discontinuous treatment, which has not been channeled in a medical emergency situation.
• • Written informed consent
• Exclusion Criteria:
• • Allergy to heparin
• • Patients treated with unfractionated sodium heparin.
• • Patients in dialysis
• • Patients with a venous catheter indicated for diagnosis tests.
• • Patients with a venous catheter indicated for blood transfusion
• • Severe heparin-induced thrombocytopenia in recent months
• • Active uncontrollable bleeding during admission
• • Brain aneurysm or dissecting aorta, except in association with corrective surgery.
• • Confirmed / suspected cerebrovascular hemorrhage
• • Severe uncontrolled hypertension
• • Severe alterations in platelet coagulation \<30,000, TP\> 1.7 APTT ratio\> 1.7 ratio.
• • Patient included in another clinical trial with drugs or procedures that may affect the patency of venous catheters.